The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic

References

• Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research (US).Guidance for industry E10 choice of control group and related issues in clinical trials. Rockville (MD): Department of Health and Human Services Food and Drug Administration (US); 2001.
   Google Scholar
• Yadav P, Vats R, Bano A, et al. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci. 2020 Oct;263:118588.
   PubMed Web of Science ®Google Scholar
• Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther. 2020 July;20(7):711–716.
   PubMed Web of Science ®Google Scholar
• Gentile P, Sterodimas A. Adipose stem cells (ASCs) and stromal vascular fraction (SVF) as a potential therapy in combating (COVID-19)-disease. Aging Dis. 2020 May;11(3):465–469.
   PubMed Web of Science ®Google Scholar
• Gentile P, Sterodimas A, Pizzicannella J, et al. Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), drugs, and vaccines in inhibiting COVID-19 disease. Aging Dis. 2020 Oct;11(5):1191–1201.
   PubMed Web of Science ®Google Scholar
• Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020 Apr;11(2):216–228.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474–e484.
   PubMedGoogle Scholar
• Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study. PLoS One. 2020;15(8):e0237693.
   PubMed Web of Science ®Google Scholar
• Rivera DR, Peters S, Panagiotou OA, et al. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer consortium (CCC19) cohort study. Cancer Discov. 2020 Oct;10(10):1514–1527.
   PubMed Web of Science ®Google Scholar
• Knight KL. Study/experimental/research design: much more than statistics. J Athl Train. 2010 Jan–Feb;45(1):98–100.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Lakzadeh P, Donato BMK, et al. Methods of sample size calculation in descriptive retrospective burden of illness studies. BMC Med Res Methodol. 2019 Jan;19(1):9.
   PubMedGoogle Scholar
• Sakai D, Chung HC, Oh DY, et al. A non-randomized, open-label, single-arm, phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Cancer Chemother Pharmacol. 2017 Dec;80(6):1197–1207.
   PubMed Web of Science ®Google Scholar
• Evans SR. Clinical trial structures. J Exp Stroke Transl Med. 2010 Feb;3(1):8–18.
   PubMedGoogle Scholar
• Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019 July;95:103208.
   PubMed Web of Science ®Google Scholar
• Donders AR, van der Heijden GJ, Stijnen T, et al. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006 Oct;59(10):1087–1091.
   PubMed Web of Science ®Google Scholar
• Pigott TD. Missing predictors in models of effect size. Eval Health Prof. 2001 Sep;24(3):277–307.
   PubMed Web of Science ®Google Scholar
• Jakobsen JC, Gluud C, Wetterslev J, et al. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017 Dec;17(1):162.
   PubMedGoogle Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011 May;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007 Nov;134(5):1128–1135.
   PubMed Web of Science ®Google Scholar
• Austin PC. Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analyses. Int J Biostat. 2009 Apr;5(1):Article13.
   Google Scholar
• Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006 June;25(12):2084–2106.
   PubMed Web of Science ®Google Scholar
• Tibshirani R. regression shrinkage and selection via the lasso. J R Stat Soc. 1996;58:267–288.
   Google Scholar
• Bhadra A, Datta J, Polson NG, et al. The horseshoe-like regularization for feature subset selection. Sankhya B. 2019. DOI:10.1007/s13571-019-00217-7
   PubMedGoogle Scholar
• Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Series B. 2005;67(Part 2):301–320.
   Google Scholar
• Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013 July;13:92.
   PubMed Web of Science ®Google Scholar
• Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96:440–448.
   Web of Science ®Google Scholar
• Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000 Sep;11(5):550–560.
   PubMed Web of Science ®Google Scholar
• Shyr Y, Shyr D. What constitutes a valid surrogate end point in cancer clinical trials? JAMA Oncol. 2020 July;6:1334.
   PubMedGoogle Scholar